Navigation Links
Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes
Date:5/20/2008

California infertility practice offering new out-patient procedures at no

charge for treating hydrosalpinx

SAN RAMON, Calif., May 20 /PRNewswire/ -- Compass Clinical Research and the Reproductive Science Center of the San Francisco Bay Area (RSC) are hoping to recruit between 20 to 50 women suffering from hydrosalpinx, a build-up of fluid in the fallopian tubes that can cause infertility, to receive free surgeries as a part of a study of the effectiveness of a new out-patient procedure used in conjunction with in vitro fertilization (IVF).

Dr. Donald I. Galen, Research Director at Compass Clinical Research and Reproductive Science Center's tubal reversal specialist and world pioneer in reproductive technological device development, will supervise the 20-minute procedures at RSC's San Ramon center. Compass Clinical Research and Reproductive Science Center, one of the first FDA's principal clinical investigative sites in the nation for early clinical trials with tubal closure devices, received both FDA and Institutional Review Board (IRB) approval for this new study.

The presence of a hydrosalpinx on one or both fallopian tubes has been associated with a reduction of approximately 50 percent in clinical pregnancy rates following IVF. Most reproductive specialists recommend surgical removal or closure (occlusion) of the impaired tube(s) before proceeding with IVF. The new ESSURE micro-insert off-label method for occluding tubes with hydrosalpinx is thought to increase chances of successful IVF, and it is a less invasive procedure with lower risks and costs than traditional surgery.

Fluid blockage in a fallopian tube, usually at the end closest to the ovary, makes it difficult for a woman to become pregnant. Traditional treatment with laparoscopic surgery involves the removal of part of the fallopian tube that generates the fluid. However, these surgeries are not always successful in achieving complete removal of problematic tissue and may cause new scar tissue and decrease healthy blood flow to the ovary that might affect pregnancy rates adhesions that interfere with successful embryo implantation. Laparoscopic surgeries also require general anesthesia, which poses higher risks of complications, involve up to a week of recovery, and cost an average of $6,500.

Compass Clinical Research's study will use a new procedure that does not involve any surgical incisions. The doctor inserts spring-like coils, called Essure micro-inserts, which are made from polyester fibers and metals like those used in heart valve replacements. They are inserted through the body's natural pathways (i.e., vagina, cervix, and uterus) and into the fallopian tubes. The inserts block the fallopian tubes, potentially preventing harmful fluids of the hydrosalpinx from flowing into the uterus and contacting the embryo. The procedure is performed under local anesthesia, so patients have a fast recovery 92 percent of women studied so far missed one day or less of work.

Three months following the procedure a hysterosalpingogram (HSG) will be performed to confirm sealing of the tubes. This X-ray test examines the interior of the uterus, the fallopian tubes, and surrounding areas. It injects a special contrasting dye through a thin flexible tube, or catheter that is inserted through the vagina and the cervix into the uterus. Because the uterus and the fallopian tubes are connected, the contrast material then flows into the fallopian tubes. As the dye circulates, X-ray pictures are taken to determine that the has been closed or occluded. At this time, the woman may proceed with IVF (separate from the no-fee Essure micro-insert procedure.)

Participation in the study may last eighteen months. As is the case for all procedures, there are possible risks associated with Essure micro-inserts, such as the possibility that the device(s) cannot be successfully placed, a risk of uterine perforation during placement, the possibility that tubal occlusion will not be successful, and the rare possibility of infection, bleeding or local anesthesia reaction. Based on Dr Galen's eight years of experience and its published clinical studies to date, these complications are very uncommon.

For more information regarding the study, please visit http://www.rscbayarea.com or call 925.973.5012.

About Reproductive Science Center

Established in 1983, the Reproductive Science Center of the San Francisco Bay Area was one of the earliest IVF facilities in the United States, begun just two years after the nation's first successful IVF treatment. RSC was among the first in the United States to report a successful pregnancy from an egg donated from one woman to another for gestation and delivery, and was also responsible for the nation's second successful transfer of a previously frozen embryo into a mother's uterus. Today, RSC boasts a staff of six infertility physicians with a collective 85 years' experience with offices in San Ramon, Orinda, San Jose, Fremont, Modesto and Brentwood. The Reproductive Science Center is a member of IntegraMed. For more information, visit http://www.rscbayarea.com.

About IntegraMed America, Inc.

IntegraMed America, Inc. is the leading operator of fertility centers in the United States. The IntegraMed Fertility network consists of 31 contracted centers in 101 locations across the United States, including 171 physicians and Ph.D. scientists. One of every five IVF procedures in the U.S. is performed in an IntegraMed fertility practice. IntegraMed also offers consumer treatment-financing programs and operates http://www.integramed.com, a leading fertility portal.


'/>"/>
SOURCE Compass Clinical Research; Reproductive Science Center ofthe San
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Best Practice Database Adds Research on Merger Integration and Competitive Intelligence
2. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
3. A research on craving for tobacco establishes the bases for addiction control
4. Performance Metrics -- Market Research Structure and Functions
5. With age comes a sense of peace and calm, population research center study shows
6. Researchers close in on new melanoma gene
7. Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report
8. Align Technology Names Dana C. Cambra as VP, Research & Development
9. Researchers develop first transgenic monkey model of Huntingtons disease
10. Researchers expand natural killer cells in cord blood to fight leukemia
11. Research talent wins national Innovation in Nursing award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: